ANDA 78789, held by PharmoBedient. Venlafaxine Hydrochloride.
As of Nov 21, 2026, ANDA 78789 (Venlafaxine Hydrochloride), held by PharmoBedient, was first approved by FDA on Jun 1, 2011, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 1, 2011 | Original application | Approved |
| Venlafaxine HydrochlorideEQ 37.5MG BASE · capsule, extended release;oral | Venlafaxine Hydrochloride | Discontinued |
| Venlafaxine HydrochlorideEQ 75MG BASE · capsule, extended release;oral | Venlafaxine Hydrochloride | Discontinued |
| Venlafaxine HydrochlorideEQ 150MG BASE · capsule, extended release;oral | Venlafaxine Hydrochloride | Discontinued |
| May 31, 2024 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jun 6, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jun 6, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jun 6, 2023 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jun 6, 2023 | Supplement 11Labeling · Standard review | Approved | None posted |
| Oct 2, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 29, 2014 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 29, 2014 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jun 1, 2011 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters